Stockwinners Market Radar for October 04, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:42 EDT GAP Airports discloses notice of tariff base regulation change - The company states: "Grupo Aeroportuario del Pacifico announced that on October 4, 2023, GAP received a notification from the Federal Civil Aviation Agency, a decentralized entity of the Mexican Secretary of Infrastructure, Communications, and Transport, informing that has decided, unilaterally and without any previous communication with the Company, to amend with immediate effect the terms of the tariff base regulation set forth in Annex 7 of the concession agreements undertaken with the SICT on June 29, 1998, as amended, in connection with the airports GAP operates in Mexico's Pacific region. GAP is currently evaluating the potential impact that the changes to the tariff base regulation may have on its business, results of operation, and financial condition."

20:05 EDT Cathie Wood's ARK Investment bought 113K shares of Block today

19:46 EDT Calliditas Therapeutics presents Phase 3 NefIgArd study data - Everest Medicines' partner Calliditas Therapeutics "presented new biomarker and subgroup analyses from Nefecon's Phase 3 NefIgArd study in both posters and oral presentations at the 17th International Symposium on IgA Nephropathy held in Tokyo, Japan. IgA-containing immune complexes have previously been shown to accumulate in renal tissue, where they trigger inflammation and scarring of the glomeruli. Investigation of the effect of Nefecon on circulating levels of IgA-IC in the Part A population of the NefIgArd clinical trial revealed that patients treated with Nefecon(R) 16mg/day exhibited a statistically significant decrease in IgA-IC levels compared to patients who received placebo when evaluated at the 3-, 6- and 9-months post randomization. Suppression by treatment with Nefecon of both IgA-IC formation and galactose-deficient IgA1 as previously reported offers an unprecedented opportunity to target the fundamental immune abnormalities that drive IgA deposition in the kidney and development of IgAN. An additional analysis of the 160 patients enrolled in Part A of the Phase 3 NefIgArd clinical study was conducted to assess the levels of three soluble factors known for modulating B cell maturation in gut-associated lymphoid tissue: B-cell activating factor, a proliferation-inducing ligand and serum B-cell maturation antigen. Compared to placebo, levels of BAFF were decreased at 3-, 6-, and 9-months after treatment initiation. Levels of APRIL were significantly reduced at the 3- and 6-months timepoints and levels of sBCMA were decreased at the 6-months timepoint. These data further support the potential disease-modifying effect of Nefecon(R) in IgAN and reinforce the central role of the gut-kidney axis in the pathogenesis of IgAN."

19:00 EDT MediciNova receives gene therapy milestone payment - MediciNova (MNOV) announced that it has received a milestone payment under MediciNova's assignment agreement with Genzyme Corporation, a subsidiary of Sanofi (SNY). The milestone payment of $1M is the result of the successful achievement of a clinical development milestone for a gene therapy product based on AAV vector technology that is covered under the assignment agreement.

18:39 EDT F&G Annuities CEO buys $132K in common stock - In a regulatory filing, F&G Annuities disclosed that its CEO Christopher Blunt bought 5K shares of common stock on October 3rd in a total transaction size of $132K. Shares are up 2% afterhours at $27.23.

18:17 EDT LGI Homes reports 540 home closings in September - LGI Homes "announced it closed 540 homes in September 2023, and a total of 1,751 homes closed during the third quarter of 2023, a 13.2% increase over the third quarter of 2022. As of September 30, 2023, the Company had 106 active selling communities."

17:52 EDT PennyMac Financial CEO Spector sells 15,000 common shares - In a regulatory filing, PennyMac Financial chairman and CEO David Spector disclosed the sale of 15,000 common shares of the company on October 2 at a price of $65.8166 per share.

17:43 EDT Alphabet exec sells $2.15M in common stock - In a regulatory filing, Alphabet disclosed that its SVP Prabhakar Raghavan sold 16.1K share of common stock on October 2nd in a total transaction size of $2.15M.

17:21 EDT SIFCO Industries regains compliance with NYSE listing requirements - SIFCO Industries received written notice from the regulation office of the NYSE American LLC acknowledging that the Company filed its delayed Form 10-Q for the fiscal quarter ended June 30, 2023 and informing the Company that it has now regained compliance with Section 1007 of the NYSE American Company Guide.

17:18 EDT Northrop Grumman awarded $178M Navy contract action - Northrop Grumman was awarded a $178M firm-fixed-price undefinitized contract action for immediate expansion of the Naval Industrial Reserve Ordnance Plant, Allegany Ballistic Laboratory. Work is expected to be completed by September 2026. FY23 weapon procurement funds in the amount of $65.28M will be obligated at time of award and will expire at the end of the current fiscal year. This contract was not competitively procured in accordance with 10 U.S. Code 3204(a)(7). Naval Sea Systems Command is the contracting activity.

17:06 EDT BlackBerry to separate IoT and Cybersecurity business units - The Board, together with its advisors, Morgan Stanley and Perella Weinberg Partners, has been evaluating a comprehensive range of strategic alternatives to drive enhanced shareholder value, including a possible separation of businesses and a range of potential sale structures. Based on input from the current process and with the support of management, the Board has determined that separating the IoT and Cybersecurity business units into two independently-operated entities is the optimal strategic direction for BlackBerry. The chief objective of the separation is to pursue a subsidiary initial public offering for the IoT business, the market leader for high-performance, safety-critical foundational software in automotive and other verticals, with a launch targeted in the first half of the next fiscal year. BlackBerry believes that a separately-traded IoT subsidiary will enable shareholders to more clearly evaluate the performance and future potential of BlackBerry's principal businesses on a standalone basis, while allowing each business to pursue its own distinct strategy and capital allocation policy. Project Imperium objectives will continue to be pursued as the company launches activities to separate our principal businesses. "The Board and management believe that separating our principal businesses will improve our ability to create value for all our stakeholders," said John Chen, Executive Chair & CEO, BlackBerry. "Both the IoT and Cyber businesses have leading technology and talent and address large and growing market opportunities. This new proposed structure will further increase both their operational agility and ability to focus on delivering exceptional solutions to their customers."

17:03 EDT Otter Tail CFO Kevin Moug to retire, Todd Wahlund to succeeed - Otter Tail announced Kevin Moug will retire on December 31 after 27 years of service to the company. Todd Wahlund will assume the role of VP and CFO to succeed Moug effective January 1, 2024. For the past 5 years, Wahlund has served as CFO and VP, Finance, at Otter Tail Power Company, the corporation's electric utility. Prior to this role, Wahlund served as VP of Financial Planning and Treasurer at the corporation, and as VP of Finance and Planning for the Varistar Manufacturing Platform. Before his time at the Corporation, he spent 20 years of increasing responsibility at Otter Tail Power Company.

16:56 EDT MongoDB Director Merriman sells $1.7M in company shares - Director of MongoDB Dwight Merriman disclosed in a regulatory filing the sale of 5,000 shares of company stock at $339.28 per share between October 2 and October 3 for a total transaction amount of $1,696,422.

16:45 EDT Electrameccanica Vehicles Corp trading resumes

16:37 EDT Rite Aid receives noncompliance notification from Nasdaq - Rite Aid announced that the NYSE informed the company that it is no longer in compliance with NYSE continued listing standards set forth in Section 802.01B and Section 802.01C of the NYSE's Listed Company Manual. Under the NYSE rules, the company is provided with certain cure periods and the company's common stock will continue to be listed and traded on the NYSE during the cure periods, subject to the company's compliance with other continued listing requirements. The current noncompliance with the NYSE listing standards does not affect the company's ongoing business operations or its U.S. Securities and Exchange Commission reporting requirements, nor does it trigger any violation of its material debt or other obligations.

16:35 EDT Cboe Global Markets reports September trading volume - U.S. Options: Cboe's proprietary product suite reported several new volume records for the month and quarter, including: Combined monthly ADV of more than 3.9M contracts; Combined quarterly ADV of 3.7M contracts; Monthly ADV of 3M contracts for S&P 500 Index options; Quarterly ADV of 2.9M contracts for SPX options.

16:32 EDT Cambium Networks cuts Q3 revenue view to $40M-$45M from $62M-$70M - Q3 consensus $64.18M. Cambium Networks expects revenues of between $40M-$45M compared to the previous outlook of $62M-$70M provided on Aug. 1, 2023. The decrease in revenues is primarily due to a delay in government defense orders due to U.S. Federal budgetary timing issues impacting the Point-to-Point business; sluggish revenues in the Point-to-Multi-Point business, which is expected until the FCC's approval and subsequent ramp of sales of Cambium's 6 GHz products; a decrease in orders and an increase in stock rotations from distributors in the Enterprise business; and continued economic headwinds, particularly in EMEA. As a result of these market challenges, Cambium Networks is suspending its guidance for the full year 2023. The company records revenues from sell-in to distributors. However, although Cambium's reported revenues declined, point-of-sale revenues-representing the sales of Cambium's products out of the distribution channel as reported by Cambium's distributors-are expected to be significantly higher for the third quarter 2023 than Cambium's reported revenues, indicating a decrease in channel inventories. Cambium expects that its reported revenues will continue to be under pressure until channel inventories return to pre-pandemic levels. The outlook for Cambium Networks' third quarter 2023 net income (loss) and income (loss) per share are expected to be below the low end of the previous GAAP and non-GAAP ranges. Cash is expected to be approximately $27M; in addition, Cambium Networks has available an unused $45M revolving credit line.

16:31 EDT Rocket Lab opens engine development center in Long Beach, CA - Rocket Lab USA officially opened the Company's new Engine Development Center in Long Beach, California. The 144,000+ square foot advanced manufacturing complex will support the high-rate production of Rocket Lab's 3D printed Rutherford engine, as well development and production for the new Archimedes engine that will power the Company's new medium-lift rocket, Neutron. The facility was formerly Virgin Orbit's headquarters and factory for the Launcher One vehicle. Rocket Lab took over the lease for the facility and acquired the factory's production assets, machinery, and equipment in May 2023 for $16.1 million, generating significant savings for the Neutron's production program.

16:28 EDT Clorox falls 5% to $125.18 after Q1 guidance

16:25 EDT Cambium Networks trading halted, news pending

16:21 EDT Clorox sees Q1 gross margin down from prior year quarter - Gross margin is now expected to be down from the year-ago quarter compared to the company's prior expectations for gross margin to be up, as provided in the Q4 earnings remarks, as the impact of the cybersecurity attack more than offset the benefits of pricing, cost savings and supply chain optimization. The impact of the cybersecurity attack on gross margin also includes lower cost absorption driven by lower volume.

16:19 EDT TC Energy finishes $5.3B sale of 40% non-controlling equity in Columbia Gas/Gulf - TC Energy announced that it has successfully completed the sale of a 40% non-controlling equity interest in its Columbia Gas Transmission, and Columbia Gulf Transmission, systems to Global Infrastructure Partners GIP for total cash proceeds of $5.3 B or $3.9B.."This sizable transaction is a tangible example of our team's focus on achieving one of our key 2023 strategic priorities of significantly advancing our deleveraging goals, ahead of our year-end target," said Francois Poirier, TC Energy's President and Chief Executive Officer. "GIP is a strong and reputable strategic and financial partner that will help unlock incremental value on our Columbia gas systems." Delivering $5+ billion of cash proceeds in a single transaction is expected to reduce TC Energy's year-end 2023 debt-to-EBITDAi leverage metric by over 0.4 times, a major step toward reaching its 2024 year-end objective of 4.75 times debt-to-EBITDA...Columbia Pipeline Group, contributed all of its equity interests in its wholly-owned subsidiaries.

16:17 EDT Dover to acquire FW Murphy for $530M in cash - Dover announced that it has entered into a definitive agreement to acquire the business of FW Murphy Production Controls for $530M in cash. The transaction is expected to close in the fourth quarter of 2023, subject to customary closing conditions, including receipt of regulatory approvals. Following the closing of the transaction, FW Murphy will become part of the Dover Precision Components operating unit within Dover's Pumps & Process Solutions segment. Founded in 1939 and headquartered in Rosenberg, Texas, FW Murphy is a provider of control, remote monitoring, digital-twin-based predictive maintenance, and adaptive performance optimization components, solutions, and instrumentation for reciprocating compressors and associated drive systems. FW Murphy's solutions are used in natural gas production, transportation, and industrial use markets, as well as in emerging hydrogen and carbon capture applications. The business is expected to generate approximately $120M in revenue in 2023, with substantial aftermarket and recurring revenue. Net of positive tax attributes, the purchase price represents approximately 13x of FW Murphy's 2023 Adjusted EBITDA, with margin accretive to Dover's consolidated margin.

16:16 EDT Semtech names Mark Lin as new CFO - Semtech announced that Mark Lin joined the company as its executive vice president and CFO on October 2, 2023.

16:15 EDT Green Brick purchased 78 homes sites in Grand Harbor in Vero Beach - Green Brick Partners announced that the Company has purchased 78 homes sites in Grand Harbor, a longstanding master-planned community in Vero Beach known for its beautiful waterfront homes and golf courses. Vero Beach is about 80 miles north of Palm Beach, FL and is an important city in the Treasure Coast area. The city features peaceful beaches and is one of the most desirable areas to live in Florida. GHO Homes, one of Green Brick's subsidiary homebuilders, has been building new homes in South Florida for more than two decades, with a focus on Florida's Treasure Coast throughout Sebastian, Vero Beach, Fort Pierce, and Port St. Lucie.

16:11 EDT Suncor to acquire TotalEnergies' Canadian operations for $1.468B - Suncor Energy (SU) announced that it has agreed to purchase TotalEnergies EP Canada Ltd., which holds a 31.23% working interest in the Fort Hills oil sands mining project for $1.468B. The acquisition adds 61,000 barrels per day of net bitumen production capacity and 675M barrels of proved and probable reserves to Suncor's existing oil sands portfolio. Regulatory approvals have been received and, subject to closing, the transaction will have an effective date of April 1, 2023.

16:10 EDT Performant Financial awarded New York Medicaid RAC Contract - Performant Financial "announced that New York State's Office of the Medicaid Inspector General awarded Performant its 2023 Recovery Audit Contractor contract following an open and competitive procurement process. This contract will run for five years, consisting of an initial three-year term, and two one-year renewals. Leveraging advanced algorithms and sophisticated reviews, Performant's best-in-class team will conduct post-payment assessments on designated claims to pinpoint and rectify improper payments."

16:07 EDT AerSale near conclusion of FAA certification process of AerAware - AerSale Corporation provided an update to the status of AerAware certification by the U.S. Federal Aviation Administration today. The company is nearing the conclusion of the FAA certification process of its Enhanced Flight Vision System "AerAware," applicable to the Boeing 737NG and MAX aircraft. Nicolas Finazzo, AerSale's Chief Executive Officer said, "Although we passed the flight-testing portion of the certification process on August 19th, there are several reports still under review by the FAA. This has led to a modestly longer-than-anticipated final approval process due in part to the 50 hours of extensive flight testing that occurred at the end of testing process, including the preparation and FAA review of post-flight summaries and final checklist items that are typical leading up to approval." Finazzo added, "To date, no material issues have been identified by the FAA, and we see no impediment to certification of this system. Following final FAA acceptance and processing of all the reports submitted, we anticipate an award of the STC."

16:02 EDT BeyondSpring receives noncompliance notification from Nasdaq - BeyondSpring announced that it received a written notification from Nasdaq that the company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550, because the closing bid price of the company's ordinary shares was below $1.00 per share for 30 consecutive business days. The notification letter does not result in the immediate delisting of the Company's Ordinary Shares and has no current immediate effect on the listing or trading of the company's Ordinary Shares on Nasdaq.

15:15 EDT WeTrade Group Inc trading halted, volatility trading pause

14:03 EDT MSC Industrial shareholders approve plan to eliminate dual class structure - MSC Industrial announced its shareholders approved the previously announced reclassification of the company's equity structure, including the elimination of the company's Class B common stock which is held by the Jacobson / Gershwind family and entities affiliated with the family. "As a result of the shareholder vote, each outstanding share of the company's high-voting Class B shares, 10 votes per share, will be exchanged for 1.225 Class A shares, 1 vote per share, in stock. Additionally, the company will adopt a majority of the shares outstanding standard, replacing the current required 2/3 vote, to approve fundamental transactions, such as a merger, and a majority of the votes cast standard for uncontested Board election. The Jacobson / Gershwind family will remain MSC's largest shareholder following the reclassification, owning approximately 21% of the company's Class A shares, and will be subject to certain standstill and lock-up provisions. The voting power of the Jacobson / Gershwind family will be limited to 15% of shares outstanding, and any shares it beneficially owns in excess of 15% will be voted pro rata with the votes of the Class A shareholders unaffiliated with the family," the company stated.

13:32 EDT RTX developing solid-state circuit breaker under NASA contract - RTX today announced it has successfully demonstrated the operation of a solid-state circuit breaker to support hybrid-electric propulsion systems in future aircraft, a key part of the aviation industry's efforts to achieve net-zero carbon emissions by 2050. The circuit breaker is being developed as part of a collaboration between the RTX Technology Research Center, Collins Aerospace and Pratt & Whitney under NASA's Advanced Air Vehicles Program. Having completed design, functional and altitude testing, RTX expects to further develop and refine the solution through system integration in Collins' new electric power systems lab-The Grid-and flight demonstration in the coming years.

12:32 EDT LiveOne reports 51,000 new premium members in September - LiveOne's CEO and Chairman, Robert Ellin, commented, "Since acquiring Slacker Radio just five years ago, annual revenue has more than tripled from $20M with a loss of $7M, to more than $60M expected for FY24 and very significant Adjusted EBITDA. Our B-to-B partnerships, which includes being part of Tesla's native connectivity app in nearly every new car sold, coupled with our consumer-friendly pricing model, has proven to be a winning combination. Given our B-to-B success with Tesla, TikTok, Samsung, Facebook and Verizon, we are aggressively expanding our sales and partnership team and expect to add multiple billion-dollar companies to the LiveOne family this year."

12:30 EDT Nuvalent Inc trading resumes

12:20 EDT Nuvalent Inc trading halted, volatility trading pause

12:00 EDT Amprius Technologies falls -14.5% - Amprius Technologies is down -14.5%, or -73c to $4.30.

12:00 EDT A10 Networks falls -28.5% - A10 Networks is down -28.5%, or -$4.33 to $10.84.

12:00 EDT Scor ADR rises 7.9% - Scor ADR is up 7.9%, or $1.35 to $18.38.

11:11 EDT AbbVie announces publication of preclinical results for ABBV-CLS-484 - AbbVie, the Broad Institute of MIT and Harvard, and Calico Life Sciences announced the publication in Nature of the discovery and preclinical data that demonstrate investigational ABBV-CLS-484 is a potential first-in-class, orally bioavailable, PTPN2/N1 phosphatase inhibitor that enhances anti-tumor immunity. The findings, based on research conducted by AbbVie in collaboration with the Broad Institute and Calico, support the development of ABBV-CLS-484 as a promising new strategy for cancer immunotherapy. Titled "The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity," the paper highlights the novel structural insights and design that led to the discovery of ABBV-CLS-484 and its dual mechanism of action that targets tumor cells and suppresses their growth, as well as promotes the activation of several immune cell types to increase their anti-tumor activity. Researchers at the Broad previously identified protein tyrosine phosphatase non-receptor type 2 and its closely related paralog PTPN1 as potential targets for cancer immunotherapy through an in vivo CRISPR screen. However, this challenging target class had previously been deemed "undruggable". AbbVie researchers overcame the challenges and discovered the dual PTPN2/N1 inhibitor, ABBV-CLS-484, through structure-based drug design and optimization of drug-like properties. Discovery scientists at AbbVie, the Broad, and Calico further uncovered the biology and mechanism of action of ABBV-CLS-484. Preclinical findings presented demonstrate that ABBV-CLS-484 treatment amplifies the tumor intrinsic response to interferon and increases the activation and function of several immune cell subsets promoting cellular pathways including JAK-STAT signaling in animal models. In murine cancer models resistant to PD-1 blockade, monotherapy ABBV-CLS-484 treatment generates robust anti-tumor immunity. Through in vivo studies and single cell transcriptional profiling of tumor-infiltrating lymphocytes from ABBV-CLS-484 treated mice, the team revealed that ABBV-CLS-484 inflames the tumor microenvironment and promotes NK and CD8+ T-cell function. In T cells, mechanistically, ABBV-CLS-484 induces epigenetic and metabolic changes resulting in a unique functional state causing increased cytotoxicity and reduced T-cell exhaustion and dysfunction.

11:02 EDT CMS Energy announces plans for solar project at former coal plant location - Consumers Energy announced new plans for an 85-megawatt solar array at the former Karn coal facilities, which closed earlier this year. The solar array project is in its early stages, and Consumers Energy continues to work closely with community members, neighbors, and local leaders to design a responsible project that fits with the community and continues the path toward renewable generation. The project could provide enough power for approximately 20,000 homes and will pay local, county and school district taxes, totaling millions of dollars over its 30-plus-year lifetime. The project, which aims to be operational by 2026, will reflect two foundational Consumers Energy goals: the significant scaling-up of renewable projects - specifically solar energy - throughout the state as part of its ambitious Clean Energy Plan, and the commitment to making a just transition for employees as part of the shift away from fossil fuels toward renewable energy sources.

10:14 EDT Uber introduces package returns with Uber Connect - Uber said on Wednesday: "Uber's mission is to change the way people, food, and things move through cities. With the launch of Uber Connect three years ago, we've simplified the way you can send items to friends, family or colleagues across town. Now we're adding a new way to save you time and effort with a much-avoided chore: taking care of the packages you need to return but have been ignoring. Your trip to the post office? With Uber Connect, it's covered. Here's how it works: With our new "Return a Package" feature, you can have a courier pick up your prepaid and sealed packages - up to five at a time - and drop them off at a local post office, UPS, or FedEx. Customers can track their package in real-time in the Uber app. The courier will send a visual confirmation or photo of the receipt when the drop-off is completed. Return a Package is a flat $5 fee-or only $3 for Uber One members. Return a Package is available starting today in the Uber and Uber Eats apps for customers in 4,950+ cities throughout the United States, including Austin, Chicago, Dallas, Denver, San Francisco and Washington DC." Reference Link

10:00 EDT B&G Foods falls -13.7% - B&G Foods is down -13.7%, or -$1.30 to $8.18.

10:00 EDT A10 Networks falls -22.6% - A10 Networks is down -22.6%, or -$3.43 to $11.74.

10:00 EDT Integrated Rail and Resources Acquisition rises 9.0% - Integrated Rail and Resources Acquisition is up 9.0%, or 98c to $11.87.

09:54 EDT Kenon announces 'favorable' ruling in arbitration proceeding - Kenon Holdings announces that an arbitration tribunal constituted by the International Centre for Settlement of Investment Disputes has delivered a final award in favor of Kenon and its wholly-owned subsidiary IC Power in an arbitration proceeding under the Free Trade Agreement between Singapore and the Republic of Peru. The arbitration related to two disputes submitted in June 2017 and November 2018 by Kenon and IC Power relating to resolutions of the mining and energy regulator in Peru on secondary frequency regulation and transmission tolls, based on events that occurred while Kenon, through IC Power, owned and operated its former Peruvian subsidiaries Kallpa and Samay I, which were subsequently sold. The claims and proceeding are described in more detail in Kenon's annual report on Form 20-F for the year ending December 31, 2022. The arbitration tribunal concluded that Peru's resolution relating to secondary frequency regulation breached Peru's obligations under Article 10.5 of the Free Trade Agreement. The tribunal dismissed the claim relating to transmission tolls. As a result of Peru's breach of the Free Trade Agreement, Peru has been ordered to pay Kenon and IC Power $110.7 million in damages. Pre-award interest is payable on the Award from November 24, 2017 to the date of the Award. Additionally, Peru has been ordered to pay Kenon and IC Power $4.9 million to cover their legal fees and expenses and a further $0.6 million in connection with Kenon and IC Power's share of the costs of the arbitral tribunal and ICSID's administrative fees. Pursuant to the ICSID Convention, Peru has 120 days from the date of the Award to file an application to annul the Award on the limited grounds established by the ICSID Convention. As previously disclosed in Kenon's Form 20-F, Kenon and IC Power have previously entered into an agreement with a capital provider to provide capital for expenses in relation to the pursuit of these arbitration claims and other costs. In the event that Kenon or IC Power receive proceeds in connection with the Award, the capital provider will be entitled to be repaid the amount committed by the capital provider and to receive up to approximately 55% of the net claim proceeds, subject to the terms of the agreement among Kenon, IC Power and the capital provider. The Award is subject to tax.

09:47 EDT Trinseo falls -11.7% - Trinseo is down -11.7%, or -97c to $7.33.

09:47 EDT Studio City rises 8.3% - Studio City is up 8.3%, or 40c to $5.24.

09:47 EDT Lithium Argentina rises 9.3% - Lithium Argentina is up 9.3%, or 57c to $6.73.

09:38 EDT Avangrid statement on northeast states regional procurement for wind power - Pedro Azagra, CEO of Avangrid, issued a statement on announcement of northeast states regional procurement for offshore wind power: "Avangrid commends Governor Maura Healey, Governor Ned Lamont, and Governor Daniel McKee for their forward-thinking and collaborative approach in announcing that Massachusetts, Connecticut, and Rhode Island will move forward with joint regional procurement for 6,000 megawatts of offshore wind power. At this critical time for the industry in the United States, as well as the rapid acceleration of the climate crisis, this bold procurement strategy rises to the level of urgency the moment demands while providing offshore wind developers an opportunity to leverage economies of scale that will unlock more competitive bids and the potential for greater investments in local development and job creation. We look forward to reviewing the final details of the procurement structure and to building on our success leading the development of the nation's first utility scale offshore wind project, Vineyard Wind 1, which is currently moving forward with turbine installation campaign with the goal of delivering first power this year.

09:35 EDT Acrivon Therapeutics Inc trading resumes

09:30 EDT Acrivon Therapeutics Inc trading halted, volatility trading pause

09:20 EDT Theralink files Form S-4, expects to complete IMAC merger in Q4 - Theralink Technologies announces the filing of a Form S-4 with the Securities and Exchange Commission requisite to complete the previously announced merger between the Company and IMAC Holdings. Upon regulatory approval, Theralink and IMAC expect to complete the Merger by the end of the current quarter.

09:19 EDT FingerMotion says Capybara short seller report contains 'many errors' - FingerMotion issued the following statement in response to the short seller report issued by Capybara Research on October 3, 2023. The company said, "Based on the review by the Company's management team, we believe that the Capybara Report contain many errors, unsupported speculations and inaccurate interpretations of events. The Company's management, together with its Board of Directors, intends to further review and examine the allegations and misinformation therein and will take whatever necessary and appropriate actions may be required to protect the interest of its shareholders. The Company is already in the process of identifying and engaging experts who can assist it in identifying the perpetrators behind this coordinated action. The Company endeavors to provide full and accurate disclosure to investors and rebut any false claims that attempt to impair market confidence in FingerMotion's business, operations and financial statements. The Company is committed to maintaining the highest standards of corporate governance, as well as transparent and timely disclosure in compliance with the applicable rules and regulations of the United States Securities and Exchange Commission and the Nasdaq rules. Furthermore, the Company recently filed the Form S-3 registration statement which was declared effective by the SEC on September 29, 2023. The Form S-3 is an unallocated universal shelf registration statement for $300 million of securities of FingerMotion of which only $25 million has been allocated to an at-the-market offering. The Company is aware that any fund raising at current levels would be entirely too dilutive to the shareholders and the Form S-3 is in place to enable thoughtful access to capital should the need arise. The Company has no current plans in place to utilize the ATM but has made the allocation in the best interests of its shareholders given the prolonged uncertainty and volatility in the capital markets."

09:15 EDT NeuroSense announces results of in vitro study of PrimeC in ALS - NeuroSense Therapeutics announced the results of a non-sponsored in vitro study of PrimeC in amyotrophic lateral sclerosis, or ALS, conducted by Justin Ichida, at the University of Southern California's, or USC, Stem Cell Ichida Lab, part of the Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research at USC. Ichida's in vitro study used induced pluripotent stem cells, or iPSCs, that were derived from blood samples of people living with ALS. The survival rate of induced motor neurons when administered with PrimeC in comparison to each of PrimeC's components, ciprofloxacin and celecoxib, alone was evaluated. PrimeC showed a significant beneficial effect relative to each of its components alone, demonstrating the synergistic effect of PrimeC and supporting the rationale of combining the two active components into NeuroSense's proprietary formulation. PrimeC attenuated ALS related pathology, as depicted by the increased survival rate. The PrimeC treated iPSCs had increased neuronal survival compared to ALS control cells, rendering their survival rate to be similar to healthy controls. Shiran Zimri, VP R&D of NeuroSense will be presenting these results at the 22nd Annual Northeast Amyotrophic Lateral Sclerosis Meeting which takes place October4-6, in Clearwater, Florida. NeuroSense expects clinical topline results from PARADIGM, its Phase 2b study of PrimeC in the treatment of ALS in the Q4.

09:10 EDT AmpliTech Group's Satcom Systems receives orders from media companies - AmpliTech Group announced new partnerships and an uptick in bookings within its Satcom components subdivision, Specialty Microwave. The division recorded $0.9 million in revenue in 2022 and has already booked $1 million just in Q2 and Q3 of this year, which the company expects to convert to revenue mostly in the first half of 2024. This achievement is attributed to Specialty Microwave securing business from global entertainment powerhouses such as Warner Bros., Disney, Paramount, and CBS Viacom.

09:09 EDT Rackspace Technology appoints Cole to board of directors - Rackspace Technology (RXT) announced the appointment of Thomas Cole to the Board of Directors. Cole is an experienced finance executive with an illustrious 37-year career on Wall Street. With extensive experience in investment banking, Cole spent 11 years at Citibank (C), where he was co-head of their leveraged finance business for the US and Canada.

09:07 EDT Taboola announces clients can now start running ads on Yahoo's properties - Taboola announced its advertiser clients can now start running native advertising on Yahoo's premier digital properties globally, in more than a dozen markets worldwide, through the Taboola advertising platform. Starting today, advertisers can access Yahoo's large portfolio of sites, supported by Taboola, including Yahoo Finance, Yahoo Mail, Yahoo News and Yahoo Sports, which reach hundreds of millions of monthly active users worldwide. Advertisers can now seamlessly run desktop mobile web and mobile app campaigns alongside Yahoo's trusted editorial environments and popular email platform. "We've seen great results for advertisers on Yahoo international markets, and I'm excited to share that we're taking a meaningful step forward to make Yahoo now available globally. With Yahoo, we're supercharging advertisers' ability to connect with millions of consumers around the world each day," said Adam Singolda, CEO at Taboola. "This adds significantly to Taboola's existing worldwide footprint and gives advertisers greater reach, better campaign performance, and a strong local team that can support advertiser success."

09:06 EDT Deutsche Telekom expands SASE portfolio powered by Fortinet - Deutsche Telekom (DTEGY) expands its security portfolio powered by Fortinet (FTNT). Deutsche Telekom is integrating FortiSASE into its offering for enterprises. "Fortinet Secure Networking solutions enable integrated telecommunications partners like Deutsche Telekom to deliver differentiated services that support enterprise customers in their SASE journeys," says John Maddison, Chief Marketing Officer and EVP, Product Strategy at Fortinet. "This collaboration is the latest example of Fortinet's commitment to providing a comprehensive single-vendor SASE solution that empowers organizations to embrace the convergence of networking and security."

09:05 EDT Shineco to increase R&D to explore new medical product applications - Shineco announced that it plans to increase its research and development of new high-tech applications of silk protein in the health and medical field in conjunction with its existing silkworm business segment. Jennifer Zhan, CEO of Shineco, commented, "We are pleased to have closed on our acquisition of a majority interest in Dream Partner, a premier manufacturer of a unique silk material products that we believe has an array of applications for the healthcare and medical products fields. We believe that its integration with our other medical product businesses will result in synergies for new specialized medical products that will be of vast benefit to healthcare consumers in China and worldwide." Shineco plans to carry out joint research work with the R&D team of Chongqing Wintus to continuously optimize and improve the extraction and processing methods of silk protein to obtain lighter and tougher silk protein materials to meet the ever-evolving needs of the health and medical fields. Shineco will integrate global sales channels, combining its existing sales network in the United States, Germany and other European and American regions, as well as Chongqing Wintus' sales network in India and other Asia-Pacific regions.

09:03 EDT RTX's Raytheon receives contract from DARPA - Raytheon, an RTX business, has received a contract from the Defense Advanced Research Projects Agency to develop Gambit, an air-breathing propulsion demonstration program that uses a novel rotating detonation engine. This type of engine is more compact, provides a higher efficiency propulsion source than conventional missile propulsion and offers the potential for lower costs. Under the contract, RTX will rely heavily on iterative development of performance models which will be anchored by real-world data from incremental system tests. This proven method accelerates learning to provide more certain flight test outcomes, saving both time and cost. Future optional phases of the Gambit program will shift to building hardware to conduct a flight weight free-jet test. With this contract, RTX becomes the first company to apply rotating detonation engine technology into an actual test system.

09:03 EDT Salem Media to sell Salem Church Products business to Gloo for $30M - Salem Media announced that it entered into an agreement to sell its Salem Church Products business to Gloo for $30M. When the transaction closes, scheduled for November 1, the parties will also enter into a $10M multi-year agreement for Salem to advertise the Gloo platform's products and services across Salem's radio and digital platform that serves the Christian audience. Salem Church Products creates and distributes resources for churches and ministries in the areas of church media, worship, children's ministry, preaching, teaching and employment through online resources including WorshipHouse Media, SermonSearch, ChurchStaffing, Children's Ministry Deals and many others.

09:02 EDT New York Times and PressReader announce new collaboration - The New York Times and PressReader announced a new collaboration to further expand The New York Times's global presence through PressReader's extensive network of channel partners which spans over 150 countries. This partnership provides an even broader global audience with unparalleled access to The New York Times's trusted journalism. Given PressReader's extensive reach, this integration will further broaden the distribution of the rich journalistic content of The New York Times. PressReader, as an industry partner of the World Travel and Tourism Council, or WTTC. PressReader's channel partners in over 150 countries are now able to get access to not only The New York Times's digital replica edition but also its digital "News" product.

08:49 EDT American Resources to sell carbon mining assets of American Carbon - American Resources Corporation's subsidiary American Carbon has entered into a letter of intent to sell its carbon mining assets to a strategic party for the total consideration of approximately $280 million. The consideration takes the form of an upfront cash payment at closing, a share of profits generated from operations, an ongoing royalty payment based on carbon sales and minority equity interest upside. The sale includes the assets of American Carbon's McCoy Elkhorn Coal, Perry County Resources and Wyoming County Coal operating subsidiaries including certain debts and environmental reclamation bonds. The letter of intent is non-binding and non-exclusive but is expected to close before year end. The proposed acquirer of the assets has committed to invest the necessary capital to bring additional mines into full production and expand the number of producing mines over American Carbon's extensive infrastructure base including the Company's Wyoming County Coal's premium mid-vol carbon complex. Concurrent with the executed letter of intent, American Resources will continue to advance its Form-10 filing of spinning-off American Carbon out into its own public, pure play metallurgical carbon growth company as an alternative opportunity while also advancing the previously announced letter of intent to sell certain assets associated to its Deane Mining complex towards closing.

08:47 EDT CACI awarded $917M, five-year contract from AFRL - CACI announced that it has been awarded a five-year contract, with a maximum ceiling value of $917M, to continue to provide complete life cycle software and systems engineering to improve battlespace awareness for the U.S. Air Force's Research Laboratory, or AFRL. The contract supports the performance, research, and gathering of data and information processing capabilities for the AFRL. Under the contract, CACI will implement Agile and adaptable processes to develop mission software and data analysis capabilities to advance and modernize command, control, communications, computers, cyber, intelligence, surveillance, and reconnaissance, or C5ISR, programs. These capabilities will enhance information dissemination and decision-making across the Air Force and intelligence community, improve information security, and meet program mission objectives.

08:46 EDT Innodata to announce AI LLM engagements with information companies - Innodata has recently signed three AI/LLM engagements with leading information companies. Innodata CEO Jack Abuhoff will make the announcement during his speaking engagement at the information industry's preeminent annual Outsell Signature Event taking place today at the Four Seasons Hampshire, England. Innodata's recently signed information industry AI/LLM deals span legal and healthcare domains and range from strategy to implementation. In one of the engagements, Innodata will be helping a leading information company create a strategic roadmap for AI/LLM integration for its products and internal operations and will be building LLM proofs-of-concept. In another, Innodata will be helping fine-tune LLMs for three customer use cases pertaining to legal services. In the third deal, Innodata will be creating medical golden datasets to train an LLM to support patient interactions while serving as a data foundation for improved search functionality, product functionality, and operational automation.

08:44 EDT ICE reports September total ADV up 6% y/y, Q3 total ADV up 8% y/y - Intercontinental Exchange reported September 2023 trading volume and related revenue statistics... "The growth in volumes and open interest, particularly across oil and natural gas where TTF had a record third quarter, reflects the strength of our energy franchise, the leadership of ICE's global energy benchmarks, and the success of Midland WTI becoming part of the Brent basket," said Ben Jackson, President of ICE. "Our soft commodities markets are trading at strong levels as our customers manage the impact of El Nino on crop harvest assumptions and their changing risk exposure to sugar, cocoa and coffee." September highlights include: Total average daily volume ADV up 6% y/y; open interest O up 4% y/y ...Energy ADV up 30% y/y; OI up 14% y/y... Total Oil ADV up 48% y/y; OI up 29% y/y......Third quarter highlights include: Total ADV up 8% y/y :Energy ADV up 30% y/y; Total Oil ADV up 40% y/y...Total natural gas ADV up 15% y/y

08:43 EDT RDE announces launch of all-new Restaurant.com mobile app - RDE announces the launch of its all-new mobile app for the iOS system Restaurant.com platform, designed to elevate the dining experience for users and provide seamless access to their Restaurant Deals. With an innovative design tailored for modern diners, this app will offer an unparalleled experience with new features and streamlined functionalities that will make it even easier for customers to find the best restaurant deals. "The Restaurant.com mobile app is poised to revolutionize the way users interact with dining deals and experiences, offering a platform that is not only easy to use but also secure and reliable," stated Ketan Thakker, CEO of RDE, Inc. "This app also opens up exciting opportunities for our restaurant partners to have greater access to their diners."

08:41 EDT VivoPower announces 1-for-10 reverse stock split - VivoPower International will proceed with a 1-for-10 reverse stock split of its outstanding ordinary shares following approval by its board of directors and as authorized by the Company's shareholders at the Extraordinary Meeting of the Shareholders held on July 6, 2023. The Reverse Split will be effective at 4:01 PM, Eastern Time, on October 5, 2023. The Company's ordinary shares will begin trading on a post-split basis at the market open on October 6, 2023. The Reverse Split is being effected primarily to increase the Company's per share trading price and to regain compliance with the $1.00 per share minimum closing price required to maintain continued listing on Nasdaq. The Company does not expect the Reverse Split to impact its current or future business operations. When the Reverse Split is effective, every 10 ordinary shares issued and outstanding will be combined automatically into one ordinary share. The Reverse Split will apply equally to all outstanding ordinary shares, and each shareholder will hold the same percentage of ordinary shares outstanding immediately following the Reverse Split, except for adjustments that may result from the treatment of fractional shares. No fractional shares will be issued in connection with the Reverse Split. In the event a holder of shares would otherwise be entitled to receive a fractional share, the number of shares to be received by such shareholder will be rounded up to the next whole number.

08:40 EDT Sigyn Therapeutics reports PCT patent submission to enhance chemo delivery - Sigyn Therapeutics disclosed the submission of a Patent Cooperation Treaty application entitled: "SYSTEM AND METHODS TO ENHANCE CHEMOTHERAPY DELIVERY AND REDUCE TOXICITY." The PCT submission is associated with medical technologies being advanced by Sigyn Therapeutics to enhance the clinical benefit of chemotherapeutic drugs administered to cancer patients. Among therapeutic technologies being developed by the Company are ChemoPrep and ChemoPure. Chemotherapy is the most commonly administered drug to treat cancer, the second leading cause of death in the United States. Despite utility across a broad-spectrum of cancers, there remains a critical need to optimize chemotherapy delivery as less than 5% of administered doses reach their tumor-site target. ChemoPrep is being advanced to extract circulating molecules that restrict the tumor-site delivery of chemotherapy and induce an unresponsiveness to therapy associated with 90% of metastatic cancer deaths. The clinical intent of ChemoPrep is to safely increase the tumor-site saturation of chemotherapeutic agents with reduced doses. Achievement of this objective will likely improve treatment outcomes yet reduce treatment toxicity and long-term health consequences associated with chemotherapy administration. Beyond the potential to increase survival and enhance patient quality of life, reduced dosing of chemotherapeutic agents may alleviate ongoing supply chain issues associated with nationwide shortages of chemotherapy. Post infusion of chemotherapy, Sigyn Therapeutics designed ChemoPure to extract off-target drug agents from the bloodstream as a means to further reduce patient toxicity.

08:39 EDT AgriFORCE Growing Systems invests in Radical Clean Solutions' technology - AgriFORCE Growing Systems announced it has purchased a 14% stake in Radical Clean Solutions, RCS. RCS, under the leadership of Roger Slotkin, has developed and is commercializing a suite of proprietary and patent-pending chemical-free Hydroxyl devices that are proven to eliminate pathogens, mold, mildew and VOCs in food production facilities, indoor farms and medical, commercial and home environments. Mauro Pennella, President AgriFORCE Brands stated, "Investing in RCS builds on our previously acquired worldwide rights to exclusively commercialize RCS' suite of Hydroxyl devices, management systems and processes in controlled environment agriculture and food manufacturing, warehousing and distribution facilities, as well as a co-ownership of the pending patent for CEA. We believe that RCS' chemical-free technologies could become a critical component for helping reduce food spoilage, ensuring maximum food safety, employee health and operational efficiency for any facility at which they are deployed. RCS' technologies are proven to eliminate foodborne pathogens like Salmonella, E. coli, and Listeria, as well as airborne and surface viruses like Norovirus, common colds and the Flu. I am especially pleased to report that our first shipments have already been delivered to our Mexico distributor, DESICO."

08:37 EDT Arcturus Therapeutics partner to receive $165M from Japanese government - Arcturus Therapeutics announced that Arcalis, Arcturus' manufacturing joint venture in Japan to support the production of mRNA vaccines and therapeutics, has been selected by the Japanese Ministry of Economy, Trade and Industry to receive additional financial support to construct a DNA template manufacturing facility along with new sequipment. In total to date, $165M has been awarded to Arcalis by the Japanese government to build mRNA Drug Substance, mRNA Drug Product manufacturing capabilities and to construct a DNA template manufacturing facility. The mRNA Drug Substance manufacturing facility was completed in July 2023. Arcalis will provide cGMP-integrated vaccine manufacturing, from mRNA drug substance to bulk nanoparticle-formulated drug product. This new capital will fund the development of a DNA plasmid production process to support the rapid manufacture of various vaccines and therapeutics, investigational drugs, and mRNA-based medicines. The new facility is designed to accelerate vaccine production by enabling the manufacturing of DNA plasmid and delivering vaccines within 100 days of the declaration of a target viral strain. The DNA plasmid generated at this facility is intended to be used as the key starting material in the manufacture of mRNA Drug Substance at the neighboring facility.

08:35 EDT Coherus Biosciences says CIMERLI sales exceed 100,000 doses - Coherus BioSciences announced that sales of CIMERLI to retinal specialists have exceeded 100,000 doses since commercial launch on October 3, 2022. CIMERLI is the first and only FDA-approved biosimilar interchangeable with Lucentis for all approved indications. In August 2023, CIMERLI achieved 25% market share of the ranibizumab market*, making it the #1 ranibizumab biosimilar. Coherus plans to report CIMERLI net sales for the third quarter when the company reports Q3 2023 financial results in November.

08:33 EDT Inhibikase Therapeutics receives FDA ODD for risvodetinib - Inhibikase Therapeutics announced that risvodetinib has been granted Orphan Drug Designation, ODD, by the U.S. Food and Drug Administration, FDA, for the treatment of Multiple System Atrophy. "We are pleased to receive orphan drug designation for risvodetinib in MSA underscoring the high unmet medical need in this patient population. There are currently no approved symptomatic or disease-modifying therapies for MSA on the market. MSA is an aggressive form of Parkinsonism, leading to death four times faster than a diagnosis of Parkinson's disease and we believe that risvodetinib could potentially slow or halt the progression of disease. As we look ahead, we are advancing our ongoing animal model studies of risvodetinib to determine its therapeutic potential to block progression and correct functional loss in MSA. These studies will form the basis of our planned Phase 2 clinical study and we look forward to providing further updates on the potential timing of the Phase 2 trial in the coming quarters. We believe proof that risvodetinib is clinically beneficial in MSA will form a basis for potential success in other forms of Parkinsonism," noted Dr. Milton Werner, Chief Executive of Inhibikase Therapeutics.

08:32 EDT China SXT Pharmaceuticals announces one-for-twenty-five reverse stock split - China SXT Pharmaceuticals announced that its Board of Directors has set the date of October 5, 2023 to be the effective date for the Company's one-for-twenty-five reverse stock split of its issued and outstanding ordinary shares. The Company's ordinary shares will begin trading on the NASDAQ Stock Market on a split-adjusted basis when the market opens on October 5, 2023. The CUSIP number for the Company's ordinary shares will be changed to G2161P140. The Company's Board of Directors approved a reverse stock split so as to regain compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Stock Market.. There can be no assurance that following the reverse split, the Company's ordinary shares will remain above $1.00 per share minimum for the requisite period as of October 30, 2023 to regain listing compliance.

08:25 EDT Salix Pharmaceuticals partners with Bellamy Young - Salix Pharmaceuticals announced its partnership with award-winning actor Bellamy Young, who is speaking out to help educate people who are impacted by hepatic encephalopathy, caused by cirrhosis. Bellamy wants those affected to know they are not alone and to help them overcome stigma that can interfere with disease education. Timed with the kickoff of liver awareness month, Bellamy is sharing her personal experience of living with a father who was suffering from HE. Bellamy's goal is to help educate patients, families and caregivers to better understand the disease and is encouraging people to visit UnderstandingHE.com, where they can access educational tools including an interactive symptom tracker and discussion guides that patients and caregivers can use to facilitate a conversation with their doctors and others.

08:24 EDT Siyata Mobile announces U.S. government order for Hero Series boosters - Siyata Mobile has received an order from the U.S. federal government for its Hero Series UM50 FN cellular boosters, which are compatible with the FirstNet wireless network.

08:23 EDT Digital Ally, Clover Leaf file SEC registration statement - Digital Ally and Clover Leaf Capital announced the filing of a registration statement by CLOE on Form S-4 with the U.S. Securities and Exchange Commission, which contains a preliminary proxy statement and prospectus in connection with the proposed business combination, announced June 2, 2023, with Kustom Entertainment, a wholly-owned subsidiary of Digital Ally. While the Registration Statement has not yet become effective, and the information contained therein is subject to change, it provides important information about the combined company's proposed business and listing of securities, Kustom Entertainment's business, as well as the proposed Business Combination, and the proposals to be considered by CLOE's shareholders. Following the closing of the business combination, CLOE will change its name to Kustom Entertainment and will operate under the same management team as Kustom Entertainment, Inc., which is currently led by Stanton E. Ross, the current CEO of Digital Ally. The transaction contemplates an equity value of $125 million for Kustom Entertainment, Inc. The combined company is expected to have an implied initial pro forma equity value of approximately $222.2 million, with the proposed business combination expected to provide approximately $18.1 million in gross proceeds from the cash held in trust by CLOE. Additionally, Digital Ally will distribute to its shareholders 15% of its shares in the combined company immediately following closing and intends to distribute the balance of such shares following a six-month lock-up period.

08:21 EDT Ocean Biomedical announces loan commitment from stockholder - Ocean Biomedical entered into a non-binding term sheet with its largest stockholder, Poseidon Bio, LLC, majority owned by Dr. Chirinjeev Kathuria, for a proposed debt facility consisting of convertible promissory notes with a principal amount of up to $10 million. The promissory notes may be issued in one or more closings and Ocean Biomedical does not expect to draw the full amount at any one closing. The promissory notes under the proposed debt facility will be unsecured general obligations of the company, junior to the company's existing senior lender, and will mature in one year following the issuance date. There will be no restrictions on the use of proceeds and interest would be payable in cash. The conversion price will be $10.34 per share, subject to certain potential adjustments. Poseidon is expected to be provided warrant coverage, with the warrants to have an initial exercise price of $11.50 per share.

08:20 EDT Ceridian launches Dayforce Autonomous Payroll - Ceridian HCM Holding launched Dayforce Autonomous Payroll, a new, automated, one-of-a-kind payroll capability that will modernize the experience for administrators. The announcement was made at INSIGHTS 2023, the company's annual customer conference being held in Las Vegas and livestreamed online. Thousands of attendees are engaging in sessions and experiences centered on helping them drive success with "A Brand New Dayforce," the conference's theme. At the conference, the company also announced plans to unify its brand to Dayforce, expected to become effective in January 2024.

08:19 EDT Ceridian introduces Dayforce Alumni Network - Ceridian HCM Holding launched Dayforce Alumni Network, a new way for organizations to connect with employees after they depart the organization. According to Ceridian's 2023 Executive Survey, 86% of global business leaders say their organization's employee alumni network is successful at filling labor and skills gaps. Dayforce Alumni Network addresses this opportunity by extending Dayforce functionality to departing employees, helping organizations expand their existing talent pools, hire vetted talent instantly, and nurture alumni through a trusted communications channel.

08:17 EDT Bolt Projects to become pubic through Golden Arrow Merger combination - Bolt Threads announced a definitive agreement for a business combination with Golden Arrow Merger Corp (GAMC) that would result in Bolt Threads becoming a public company. Upon closing of the transaction, the combined company will be named "Bolt Projects Holdings, Inc." and is expected to remain listed on Nasdaq under a new ticker symbol (BSLK). Bolt Threads Founder and CEO Dan Widmaier will lead the combined company. Golden Arrow has agreed to combine with Bolt Threads based on a $346.1M pro forma enterprise valuation. The transaction is expected to deliver at least $35M of gross proceeds to the company, consisting of an interim bridge financing of up to $6.8M, $5.5M of which was funded in connection with the signing of the business combination agreement and a fully committed common stock PIPE of up to $28.7M that will fund at the consummation of the business combination. The financing is anchored by existing Bolt Threads' stockholders that include Baillie Gifford, Temasek, Top Tier, Founders Fund, Formation 8, and Foundation Capital, and a total investment of up to $10M from the Golden Arrow sponsor. Additionally, Golden Arrow's trust account of $21.5M may deliver additional proceeds to the company at closing of the business combination transaction. The transaction has been unanimously approved by the boards of directors of each of Golden Arrow and Bolt Threads and is subject to approval by each party's respective stockholders and other customary closing conditions. The transaction is expected to close in the first quarter of 2024.

08:16 EDT BigBear.ai simulation for AutoCAD showcased by Autodesk CEO - BigBear.ai was prominently demonstrated alongside Autodesk CEO Andrew Anagnost, showcasing the partnership's AutoCAD discrete event simulation functionality at Autodesk's annual Digital Convergence Event. This year's event focused on the integration of facility design with production system design. Andrew Anagnost, CEO of Autodesk, shared his vision of creating frictionless interfaces between architects, process engineering, design, and operations. Andrew spoke to the importance of converging workflow between manufacturing and architectural design, and the need for advanced toolsets to predict design success before investing capital. Autodesk has teamed with BigBear.ai to deliver this vision to designers, builders, and planners in engineering and manufacturing around the world. Autodesk's solutions are now directly integrated with BigBear.ai's ProModel Discrete Event Simulator, enabling users to accurately simulate entire multi-faceted systems inside of AutoCAD, the world's market-leading architectural engineering and construction design platform. Combined with the power of Autodesk's Factory Design Utilities, these simulation capabilities provide not only the spatial representations of the planned space in 2D and 3D, but also provide planners with actionable insights to plan and execute on installation and confirmation of optimally cost-effective and agile project solutions. As a result, AutoCAD professionals are empowered with confidence that their design will produce the correct number of products in the desired amount of time, before ever spending a dollar on implementation, trial, and error.

08:15 EDT Ceridian launches Dayforce Exchange - Ceridian HCM Holding launched Dayforce Exchange, an open and connected marketplace that extends the Dayforce experience across applications, data, content, and the workforce. Comprised of three distinct yet unified pillars - Talent Exchange, Solution Exchange, and Partner Exchange - Dayforce Exchange extends the Dayforce platform's unique HCM capabilities across internal and external networks, without extra navigation or login experiences. One security model, one sign-on, and the same single data model that Dayforce provides ensures reliability and compliance.

08:14 EDT Alpine Immune Sciences appoints Wolfgang Dummer to CMO - Alpine Immune Sciences (ALPN) announced the appointment of Wolfgang Dummer to chief medical officer effective October 2. He succeeds Andrew Sandler, who will transition responsibilities to Dummer through the remainder of the year. He joins Alpine from Rigel Pharmaceuticals (RIGL), where he served as chief medical officer.

08:14 EDT Acumen to present deeper insights from Phase 1 study of ACU193 - Acumen Pharmaceuticals announced that it will present deeper insights and new exploratory findings from its Phase 1 INTERCEPT-AD trial evaluating ACU193, the first clinical-stage AbetaO-directed antibody therapy for early AD, at the 16th Annual Clinical Trials on Alzheimer's Disease conference taking place in Boston and online from October 24-27, 2023. INTERCEPT-AD was selected to be featured in a symposium on Friday, October 27, and data from exploratory analyses of the Phase 1 trial will also be shared in two in-person and two virtual poster presentations. Decades of research have shown that soluble AbetaOs are a highly toxic form of Abeta, based on their propensity to bind to neurons, disrupt synapses and contribute to tau hyper-phosphorylation. ACU193 is the first clinical-stage antibody designed to selectively bind AbetaOs, inhibiting their ability to disrupt synaptic function, while potentially offering improved safety and clinical benefit over existing amyloid-directed therapies. In July of this year, Acumen announced topline results from its INTERCEPT-AD trial which demonstrated that ACU193 was well-tolerated with a compelling overall safety profile, meeting the primary objective of this Phase 1 study in both single and multiple doses in 60 participants with early AD.

08:12 EDT Bitcoin Depot amends equity support agreement - Bitcoin Depot announced the execution of an amendment to the PIPE Agreement dated June 23, 2023 between the Company, certain of its subsidiaries and the subscribers thereto. Pursuant to the Amendment and upon the closing of the private sale by the Subscribers of all of their shares of Series A Convertible Preferred Stock of the Company as discussed below, all Reference Periods will be pulled forward and the economic arrangements set forth in the forward agreement provisions in the PIPE Agreement settled in full based on the net price in the private sale. The Company will receive a small payment in connection with the settlement of the Reference Periods.

08:11 EDT Graphic Packaging to decommission K3 CRB machine in Michigan - Graphic Packaging Holding announced it will permanently decommission the K3 coated recycled paperboard, or CRB, machine in Kalamazoo, Michigan. The K3 machine is one of three CRB machines at the Kalamazoo facility and is the company's longest-running machine. K3 ceased operation on July 1 and today's announcement reflects the decision to permanently shut down the 125,000-tons per annum machine. Removing higher-cost, less efficient production capacity is part of Graphic Packaging's CRB optimization plan first announced in 2019 alongside the transformational investment in a new, state-of-the-art K2 CRB machine. Permanently decommissioning the older machine is the company's next step of network optimization. The machine decommission is not expected to have any impact on the company's 2023 projected Adjusted EBITDA of $1.9B, the midpoint of the previously provided guidance range.

08:10 EDT Royale Energy provides operations update on Permian Basin JDA - Royale Energy announces new progress on its Joint Development Agreement with Ares Energy LTD, located in the Permian Basin, Texas. This project is a horizontal resource play in the Mississippian interval. Royale and its investors have a 5% Working Interest in the first two wells drilled and 7% Working Interest in the third and fourth wells drilled on the 6,900 net acres project located in Ector County, Texas. To date there have been four wells drilled on this acreage. The first well that was completed in March 2023 demonstrated an initial production rate of 818 BOPD & 1,100 MCFD with expected reserves exceeding 1,400,000 barrels of oil equivalent. The second well was completed in August 2023, and has demonstrated an initial rate of 1,347 BOPD & 1,649 MCFD with expected reserves exceeding 1,500,000 barrels of oil equivalent. The third and fourth wells have been drilled and are currently being completed with production expected to begin in early October 2023. We anticipate drilling one more well in 2023 and three to six more wells in 2024 on this project.

08:09 EDT Hormel Foods commits to reduce GHG emissions 50% by 2030 - Hormel Foods recently had its greenhouse gas, or GHG, reduction targets validated by the Science Based Targets initiative, or SBTi. The company has committed to reduce absolute GHG emissions from its operations 50% by 2030 from a 2019 base year. Hormel Foods also commits to reduce absolute GHG emissions within its supply chain 27.5% within the same timeframe. The company's ambitious targets are in line with the trajectory established during the Paris Climate Agreement to limit average temperatures rising by more than 1.5 degrees Celsius above pre-industrial levels. The company has already taken a variety of measures to reduce greenhouse gas emissions, including its energy efficiency and reduction efforts. In 2022, Hormel Foods increased its procurement of domestic renewable electricity from less than 10% to 100% through Power-Purchase Agreements that generate over 936 million kWh hours during 2022. For these efforts, the company has received awards from the Environmental Protection Agency and the Center for Resource Solutions.

08:08 EDT Constellium completes the sale of its Landau, Crailsheim, Burg facilities - Constellium announced the completion of the sale of three of its soft alloy extrusion facilities located in Landau, Crailsheim and Burg in Germany to Vaessen Aluminium, for a total cash consideration of EUR 48.8 million. This announcement follows the completion of the regulatory approval process.

08:06 EDT Standard BioTools, SomaLogic to combine in all-stock merger - Standard BioTools (LAB) and SomaLogic (SLGC) announced that they have entered into a definitive agreement to combine in an all-stock merger. The combined company, with a pro-forma equity value of over $1 billion based on Standard BioTools' closing share price on October 3, 2023, will be a leading provider of differentiated multi-omics tools for research. With products distributed in approximately 50 countries and a global infrastructure, the combined company would become a leading platform of multi-omic technologies with over $180 million of pro-forma combined revenue for the full year 2023 and a robust balance sheet with over $500 million in estimated cash and cash equivalents at close. Under the terms of the agreement, which was unanimously approved by the participating members of the boards of directors of both companies, SomaLogic shareholders will receive 1.11 shares of Standard BioTools common stock for each share of SomaLogic common stock owned. Upon the close of the transaction, Standard BioTools shareholders will own approximately 43% of the combined company, and SomaLogic shareholders will own approximately 57% of the combined company on a fully diluted basis. Strategic and Financial Benefits: reates a multi-omic technology leader, targeting large, high growth markets with a diverse portfolio of life science tools that power industry-leading throughput and data quality. Expands commercial reach and maximizes cross-selling opportunities through complementary offerings and end markets. Standard BioTools' strong presence in academic research settings ideally complements SomaLogic's prestigious biopharmaceutical research footprint. Expedites scalability creating an accelerated path to combined company profitability. The transaction is expected to generate $80 million in annual cost synergies by 2026. Produces a formidable capital structure with over $500 million in cash and cash equivalents expected at close to self-fund future growth initiatives. Opens the door to meaningful value creation through a proven model that couples deep large-enterprise life sciences expertise and operating discipline with ample capital. The combined company will be led by an experienced Board of Directors and leadership team that leverages the deep life sciences expertise within both organizations. Upon close, the combined company's Board will consist of seven directors, three of whom will be designated by Standard BioTools: Michael Egholm, Fenel Eloi and Frank Witney, and three of whom will be designated by SomaLogic: Tom Carey, who will serve as Chairman, Troy Cox and Kathy Hibbs. Eli Casdin will also continue to serve on the combined company's Board. Upon close, Michael Egholm will serve as Chief Executive Officer, Jeff Black will serve as Chief Financial Officer and Alex Kim will serve as Chief Operating Officer. Adam Taich will serve as the combined company's Chief Strategy Officer, and Shane Bowen, Chief Research and Development Officer of SomaLogic, will serve as Chief Technology Officer. The combined company will operate under the Standard BioTools name with facilities in California, Colorado, Massachusetts, Canada and Singapore. The transaction is expected to close in the first quarter of 2024, subject to approval by both companies' stockholders, expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and satisfaction of other customary closing conditions. Stockholders representing approximately 16% of Standard BioTools common stock and approximately 1% of SomaLogic common stock, including the directors and executive officers of each company and affiliated investment funds, have entered into voting agreements in support of the transaction.

08:04 EDT Loop Media announces full migration to AWS including Amazon RDS for scalability - Loop Media (LPTV) announced that Loop Media has fully migrated its platform infrastructure to Amazon (AMZN) Web Services, AWS, including Amazon Relational Databases RDS use for scalability and reliability, Amazon CloudFront for all media delivery, and Amazon Elastic Compute Cloud EC2 for all server deployments. The company leveraged the AWS Startups program, which focuses on helping startups succeed by offering a broad range of infrastructure services, programs, and events to support startups as they launch, grow, and scale. The expanded business relationship between Loop(R) and AWS includes usage of 35 different AWS services every month on average, as well as Multi-Channel Fulfillment (MCF) and Fulfillment by Amazon (FBA), which now enables Loop Media to rapidly integrate new services to the platform, while simultaneously benefiting from operational cost savings.

08:04 EDT Daxor awarded support from NIH catalyze preclinical services program - Daxo announces it has been accepted into the National Institutes of Health, NIH, Catalyze Preclinical Services Program. This program supports preclinical development, including studies and activities needed to meet the regulatory requirements for therapeutic and device submissions of technologies relevant to the National Heart, Lung, and Blood Institute's mission. This effort will be done in collaboration with two nationally recognized contract research organizations, to support the continued development of Daxor's non-nuclear fluorescent blood volume analyzer device. "This exciting initiative will facilitate a tracer with practical applications in settings as diverse as a doctor's office to critical care units or even intraoperatively as well. We are gratified to receive the valuable support of the NIH's Catalyze Program which recognizes the significant impact that this technology will bring once commercialized. The capacity to improve outcomes for millions of patients at multiple points within the healthcare system is exactly the innovative work that fits within the scope of the Catalyze Program and Daxor's vision - optimal blood for all," said Michael Feldschuh, Daxor's CEO and President. The Catalyze Program is an ultra-selective initiative to fund the most promising future medical innovations by the NIH. The Catalyze Program is designed to fund key preclinical research of technologies and transformative platforms by NHLBI. Daxor will receive support and direct funding from third-party labs to conduct needed preclinical work toward an FDA submission of its next generation non-nuclear tracer system. This initiative is separate from the existing initiative to launch a next generation bedside analyzer that is undergoing validation in preparation for an FDA submission slated for before the end of 2023

08:02 EDT American Outdoor Brands names Brent Vulgamott as COO - American Outdoor Brands (AOUT) announced that Brent Vulgamott, Vice President of Sales, Operations & Analytics, has been named to the newly created role of COO, under which he will continue to lead all facets of the Company's Sales, Operations, and Analytics functions. Prior to American Outdoor Brands, Vulgamott served in a variety of increasingly responsible roles for the Outdoor Products & Accessories Division of Smith & Wesson Brands (SWBI), most recently as Vice President of Operations.

07:49 EDT SCPNG grants exemptions to allow Newmont to proceed with Newcrest deal - Newmont announced that the Securities Commission of Papua New Guinea or SCPNG, has granted the necessary exemptions and other requested confirmations under PNG capital markets law to allow the Company to proceed with its proposed acquisition of Newcrest Mining Limited. Last week, the Philippine Competition Commission, PCC, also indicated its approval of the proposed transaction. All of the government regulatory approvals necessary for the transaction to proceed have now been secured. Newmont's President and Chief Executive Officer, Tom Palmer, thanked PNG's government and went on to state, "We look forward to building strong and mutually beneficial partnerships with the government and people of Papua New Guinea to generate lasting shared value and meaningful economic development through the world-class Lihir gold mine and the highly prospective Wafi-Golpu gold and copper project. As the world's leading gold company, we recognize PNG's significant, untapped economic potential and support providing its citizens the opportunity to invest in and benefit from our operations, projects and social contributions." Newmont recently announced it has taken steps to establish a dedicated Business Unit in PNG with the appointment of Alwyn Pretorius who will assume the role of Managing Director and be based in Port Moresby. Newmont also plans to establish a secondary listing of Newmont stock depositary interests on the PNGX from closing of the transaction. ..Newmont and Newcrest anticipate the transaction closing in the fourth quarter of this year, subject to the satisfaction of customary closing conditions. Newmont stockholders will vote on the proposed transaction on October 11 and Newcrest's shareholder vote will take place on Friday, October 13...

07:41 EDT Nice to acquire LiveVox for $3.74 per share in cash, sees accretion - Nice (NICE) and LiveVox (LVOX) announced that Nice has entered a definitive agreement to acquire LiveVox. Under the terms of the merger agreement, at the closing of the transaction LiveVox stockholders will receive $3.74 in cash for each share of LiveVox common stock. The merger agreement has been approved by the boards of directors of Nice and LiveVox. Following entry into the merger agreement, the holders of a majority of the outstanding shares of LiveVox approved the merger agreement by written consent, and no other approval of LiveVox stockholders is required. The transaction is expected to close in the first half of 2024, subject to certain regulatory clearances and other customary closing conditions. Upon completion of the transaction, LiveVox will no longer be publicly listed or traded on Nasdaq. The transaction is expected to be cash flow positive and accretive to NICE's operating income, operating margin and non-GAAP EPS during 2024. The transaction will not impact NICE's share buyback program.

07:39 EDT Baker Hughes announces milestone electric-LNG award for ADNOC Ruwais LNG - Baker Hughes announced Wednesday it has received a letter of award by ADNOC Gas, for and on behalf of ADNOC, to provide two electric liquefaction systems, e-LNG, for the Ruwais LNG project in the United Arab Emirates. The award is expected to be booked in the fourth quarter of 2023 and was announced at this year's ADIPEC, one of the largest energy industry events in the world. The LNG trains will be driven by Baker Hughes' 75 megawatt BRUSH electric motor technology and feature the company's compressor technology, making Ruwais LNG one of the first all-electric LNG projects in the Middle East. Through the Ruwais LNG growth project, ADNOC intends to more than double its LNG production capacity to meet increased global demand for natural gas. "This award represents an important milestone for Baker Hughes in the LNG market and demonstrates the strength of our portfolio, which we strategically expanded through the BRUSH Power Generation acquisition in 2022," said Ganesh Ramaswamy, executive vice president of Industrial & Energy Technology at Baker Hughes. "Over the next decade, electrification will play a critical role in the energy transition, enabling further reduction of the carbon emissions footprint of natural gas. We are incredibly honored that ADNOC Gas, for and on behalf of ADNOC, has chosen Baker Hughes as a trusted partner to support their vision to increase LNG production while further decarbonizing their operations."

07:38 EDT MyMD Pharma to present 'statistically' significant Phase 2 data for MYMD-1 - MyMD Pharmaceuticals, announced that it plans to share information on the Company and its product pipeline, including an update on recent positive phase 2 study results for MYMD-1 in sarcopenia, at the upcoming BioFuture 2023 Meeting. MyMD recently announced positive topline Phase 2 study results in participants with sarcopenia/frailty which showed MYMD-1 demonstrated statistical significance in reducing serum levels of TNF-a, IL-6 and sTNFR1, biomarkers common to a number of chronic inflammatory diseases, and met all primary pharmacokinetic and secondary safety and tolerability endpoints across multiple doses over 28 days of treatment. New key findings from the Phase 2 study showed that cohort 4 showed a reduction in TNF-a, a key cytokine, across 28 days versus placebo. "The scientific data clearly indicate statistical significance across 28 days at the high dose group and we are extremely excited about the completion of the phase 2 clinical trial," said Dr. Chris Chapman, MD, president, director, and chief medical officer at MyMD Pharmaceuticals. Continued Dr. Chapman, "We are pleased to share information about our company and pipeline at BioFuture 2023, particularly related to our lead candidate and next generation TNF-a inhibitor, MYMD-1, which we believe is showing tremendous promise in inflammatory diseases. Its potential to ease the burden of these diseases, which affect millions of patients, caregivers and their healthcare professionals, is what compels us to continue this important research." The Company will present the clinical safety report to the FDA with plans to seek future guidance for a Phase 3 clinical trial in sarcopenia. If approved, MYMD-1 has the potential to be the first drug approved by FDA for the condition, an age-related decline in muscle mass and physical function which leads to greater risk of hospitalization, disability, and death.

07:37 EDT Vision Marine Technologies announces delivery of e-motion electric powertrain - Vision Marine Technologies announces the delivery of its pioneering E-Motion Electric Powertrain Technology to Groupe Beneteau, Four Winns at their production facility in Michigan. In a strategic move to underscore the dawn of a new era in eco-friendly marine transport, these boats will embark on a voyage to Europe, where they will be proudly showcased at the esteemed Dusseldorf boat show from January 20-28, 2024. The event, renowned for presenting breakthroughs in the boating world, will serve as the perfect platform to highlight the exceptional capabilities and innovations of the E-Motion powered boats. Following this debut, The E-Motion 180E equipped boats will be delivered to their ultimate owner, marking a significant milestone - the first-ever electric boats coming off the Four Winns production line destined for consumer ownership. Alexandre Mongeon, CEO of Vision Marine, expressed his excitement, stating, "The pioneering efforts of Groupe Beneteau and their dedicated production team, in crafting a specialized assembly line for electric boats, not only sets the course for the future; but also fortifies Four Winns with a distinct advantage against any subsequent boat manufacturer venturing into electrification."

07:36 EDT BioPlus Acquisition announces intention to liquidate - BioPlus Acquisition announced BIOS, Avertix Medical, Inc. and certain other parties have mutually agreed to terminate their previously announced business combination agreement and plan of reorganization, effective as of October 4, 2023 and it intends to liquidate as soon as practicable after October 4, 2023 and to return funds to holders of its Class A ordinary shares that were included in the units issued in the Company's initial public offering. The Business Combination Agreement was dated as of May 2, 2023. The parties have signed an agreement terminating the Business Combination Agreement on mutually acceptable terms, which also makes void the ancillary documents to the Business Combination Agreement. In view of the termination of the Business Combination Agreement, BIOS determined that it would be unable to consummate an initial business combination within the time period in its Amended and Restated Memorandum and Articles of Association, as amended and BIOS intends to dissolve and liquidate in accordance with the provisions of its Charter. BIOS expects to redeem all of its Public Shares for an estimated redemption price of approximately $10.79 per share after the payment of taxes and dissolution expenses. Record holders will receive their pro rata portion of the proceeds of the trust account by delivering their Public Shares to Continental Stock Transfer & Trust Company, the Company's transfer agent. Beneficial owners of Public Shares held in "street name," however, will not need to take any action in order to receive the redemption amount. The redemption of the Public Shares is expected to be completed within ten business days after October 4, 2023. The Company's sponsor has agreed to waive its redemption rights with respect to its outstanding Class B ordinary shares issued prior to the Company's initial public offering and the Class A ordinary shares contained in the units issued in a private placement concurrent with the initial public offering. There will be no redemption rights or liquidating distributions with respect to the Company's warrants, which will expire worthless.

07:33 EDT Essential Utilities unit to acquire water system in Greenville, PA for $18M - Essential Utilities announced its Aqua Pennsylvania subsidiary signed a purchase agreement to acquire the water system in Greenville, PA for $18M. The transaction is expected to close in the third quarter of 2024. The water treatment plant and distribution system are currently operated by the Greenville Municipal Water Authority. The system consists of 40 miles of main line in Greenville, Hempfield Township and West Salem Township with nearly 3,000 service connections. The transaction builds on Essential's strategy to invest in system operations, employees and infrastructure that deliver clean, safe, reliable natural resources to residential and business customers, including water and wastewater services, with a focus on positively impacting the environment. "

07:33 EDT Theratechnologies receives January 2024 PDUFA goal date for tesamorelin sBLA - Theratechnologies announced that the U.S. Food and Drug Administration, FDA, has assigned a Prescription Drug User Fee Act, PDUFA, goal date of January 22, 2024 to the Company's supplemental Biologics License Application, sBLA, of the F8 formulation of tesamorelin. In accordance with the FDA's standard review practices, unless the Company is notified before November 21, 2023, that the application is not sufficiently complete to permit a substantive review, the FDA will file the sBLA for the F8 formulation of tesamorelin.

07:32 EDT Hycroft Mining provides update on Nasdaq listing requirements - Hycroft Mining Holding announces that, as anticipated, today it received a notice from Nasdaq indicating the Company's shares would be delisted on October 12, due to non-compliance with Nasdaq's minimum bid price requirement as set forth in Nasdaq's Listing Rule 5550. However, the delisting process will be stayed and the Company's stock will continue to trade if the Company requests a hearing before the Nasdaq Hearings Panel no later than October 10, 2023. The Company intends to file its hearing request on October 9. The Company is diligently working to regain compliance with the minimum bid price requirement and will provide an update when relevant information becomes available.

07:28 EDT Flyht Aerospace, Canada Jetlines partner for hardware, software solutions - FLYHT Aerospace Solutions and Canada Jetlines Operations announced an agreement for the purchase of FLYHT's hardware and software solutions. The adoption of these solutions will help enable Canada Jetlines to optimize its long range communications, flight and turn management operations, and provide an expandable platform for Canada Jetlines to grow its automated data collection, communications and connectivity strategies for its fleet of Airbus A320 aircraft. The contract is valued at approximately $3.2 million, provided that all products and services are delivered over the term of the agreement. Installations are expected to commence in October 2023.

07:24 EDT Phoenix Motor launches Gen 4 retrofit electrification solutions - Phoenix Motor announced the launch of its Gen 4 retrofit electrification solution for medium-duty vehicles. The company's fourth generation electric drive system can be utilized to electrify a range of current internal combustion engine vehicles including shuttle buses, school buses, paratransit buses, box trucks, cargo vans and various work trucks. Phoenix Motorcars retrofit solutions aim to alleviate the two key challenges faced by fleets in switching to electric: the incremental cost of new EVs; and, long lead times due to limited availability. The ability to utilize Phoenix's retrofit solution allows fleets to electrify their existing assets, significantly lower capital requirements and reduce the time to deploy zero-emission alternatives. The Company believes its retrofit solution should enable an alternative pathway to satisfy certain regulations that require fleets to achieve zero-emission milestones starting in 2024.

07:19 EDT Xortx Therapeutics calls special meeting of shareholders - XORTX Therapeutics announces that the Company has called a special meeting of shareholders for 10:00 a.m. on October 25, 2023. Materials for the Meeting have been mailed to shareholders and are available on the Company's SEDAR profile and the Company's website. The meeting has been called for shareholders to consider a consolidation of the Company's issued and outstanding shares in order for the Company to comply with continued listing requirements for the NASDAQ Capital Market.

07:17 EDT NFI Group announces battery pack supply agreement with American Battery - NFI Group announced a partnership with American Battery Solutions for the supply of custom battery packs to power NFI's battery-electric transit buses and coaches in North America that will increase capacity and add resiliency to NFI's North American battery supply. "Demand for battery-electric buses is accelerating, and we are leading the evolution to zero-emission public transportation. Our partnership with ABS will provide NFI with the capacity, flexibility, and resiliency we need as we ramp up production at our facilities across North America," said Chris Stoddart, President, North American Bus and Coach, NFI. "ABS has made significant investments in their pack assembly and battery technology, providing us with industry leading solutions. We look forward to working together with ABS to advance battery technology for public transportation." NFI entered into a five-year agreement with ABS in 2021 and, following two years of extensive development and testing, NFI is now launching ABS batteries into bus production for customer deliveries starting in the first quarter of 2024. ABS will act as a second battery supplier to NFI, and will support NFI's significant battery-electric production ramp-up planned for 2024 and 2025.

07:15 EDT BioCryst reports inducement grants under Nasdaq listing rule - BioCryst Pharmaceuticals announced that the compensation committee of BioCryst's board of directors granted 23 newly-hired employees stock options to purchase an aggregate of 128,800 shares, and restricted stock units covering an aggregate of 88,650 shares, of BioCryst common stock. The options and RSUs were granted as of September 29, 2023, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $7.08 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee's continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst's Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.

07:13 EDT Viracta Therapeutics to host R&D Day highlighting Nana-val - Viracta Therapeutics plans to highlight new preliminary clinical and preclinical data from studies of nanatinostat and valganciclovir, its all-oral investigational therapy targeting Epstein-Barr virus associated cancers, during an R&D Day, Wednesday, October 4, 2023, at 8:00 a.m. EDT. The R&D Day will feature presentations by members of Viracta's senior management team focusing on its highest priority EBV+ lymphoma indications in the pivotal NAVAL-1 trial, namely, peripheral T-cell lymphoma and diffuse large B-cell lymphoma as well as its advanced EBV+ solid tumor program in patients with recurrent or metastatic EBV+ nasopharyngeal carcinoma. In addition, the R&D Day will feature presentations by expert key opinion leaders who will discuss the high unmet medical needs of EBV-associated lymphomas. Initial preliminary data from the pivotal NAVAL-1 clinical trial of Nana-val in patients with relapsed or refractory EBV+ lymphoma: As of the data cutoff date of June 30, 2023, initial results from the first five patients with R/R EBV+ PTCL treated with Nana-val showed an overall response rate and complete response rate of 40%. The EBV+ PTCL cohort met the efficacy threshold for expansion into Stage 2 of the study, which was based upon having achieved two objective responses within the first five of 10 patients to be enrolled in Stage 1 of the study. Median duration of response has not yet been reached. Anticipated 2024 milestones: Completion of enrollment into Stage 2 of the R/R EBV+ PTCL cohort, Engagement with FDA on additional requirements for accelerated approval, Presentation of Stage 2 data. Additional response and durability assessments from the Phase 1b/2 trial of Nana-val in patients with R/R EBV+ lymphoma as of the May 4, 2023 data cutoff date: Median DoR for patients with R/R EBV+ PTCL was 17.3 months with an ORR/CRR of 50%/38%. In patients with R/R EBV+ DLBCL, additional response assessments from a formulation pharmacokinetics bridging substudy included two additional responders, one complete response and one partial response, resulting in an ORR/CRR of 67%/33%. Median DoR in the R/R EBV+ DLBCL cohort has not yet been reached, with three patients remaining in response and on continued study treatment with DoRs of 11.1 months, 36.8 months and 41.9 months/ Additional follow-up further demonstrated that Nana-val was generally well tolerated with manageable, if not reversible, low-grade toxicities; the most commonly observed treatment-emergent adverse events were hematologic or gastrointestinal in nature as well as low-grade creatinine elevations. New interim clinical data in Phase 1b/2 study of Nana-val in advanced EBV+ solid tumors highlight the opportunity to dose escalate further with an innovative dosing regimen supported by new preclinical data to potentially drive additional responses in this patient population: Enrollment completed through the fifth dose level of the Phase 1b dose escalation portion of the trial without any dose-limiting toxicities reported. Best responses to date included two PRs at the higher dose levels plus five stable diseases in 17 patients with R/M EBV+ NPC. In a preclinical murine EBV+ gastric cancer xenograft model, split daily Nana-val dosing had superior anti-tumor activity than intermittent once-daily dosing, which supports the evaluation of this split daily dosing regimen in patients with advanced EBV+ solid tumors. Anticipated 2024 milestones: Up to three additional dose levels are planned with Nana-val on an SDD schedule to select a recommended Phase 2 dose, Initiation of the clinical trial's randomized Phase 2 expansion cohort designed to evaluate Nana-val at the recommended Phase 2 Dose with or without pembrolizumab in patients with R/M EBV+ NPC, Initiation of the clinical trial's exploratory Phase 1b expansion cohort designed to evaluate Nana-val at the RP2D in patients with other advanced EBV+ solid tumors, including gastric carcinoma, leiomyosarcoma, and lymphoepithelioma.

07:11 EDT Tonix announces issuance of EU patent covering intranasal potentiated TNX-1900 - Tonix Pharmaceuticals announced that the European Patent Office, EPO, issued European Patent No. 3242676 to the Company on October 4, 2023. The patent, entitled "Magnesium-Containing Oxytocin Formulations and Methods of Use", claims methods and compositions for treating pain, including migraine headaches, using intranasal magnesium-containing oxytocin formulations. This patent, excluding possible patent term extensions, is expected to provide Tonix with market exclusivity in the member states of the European Patent Office until 2036. The U.S. Patent and Trademark Office (USPTO) has previously issued U.S. Patents No. 9,629,894 and 11,389,473 which are expected to provide market exclusivity in the U.S. until 2036. In August 2023, Tonix announced it completed enrollment in its proof-of-concept Phase 2 PREVENTION study of TNX-1900 for the prevention of migraine headache in chronic migraineurs with a total of 88 patients enrolled. The Company expects topline results from this trial in early December 2023.

07:10 EDT Civitas in pact with Vencer to acquire accretive Permian Basin assets for $2.1B - Civitas Resources signed an agreement with Vencer Energ a Vitol investment, to acquire oil producing assets in the Midland Basin of west Texas for a total consideration of approximately $2.1B, subject to customary terms, conditions, and closing price adjustments . The Acquisition is expected to close in January 2024 with an effective date of January 1. Attractively priced and immediately accretive to Free Cash Flow per share: The Acquisition is attractively priced at 2.8x 2024 estimated Adjusted EBITDAX at $80/Bbl NYMEX WTI and $3.50/MMBtu NYMEX Henry Hub, which compares favorably to recent transactions in the Permian Basin. Approximately 80% of the purchase price is underwritten by the value of proved developed and proved developed non-producing reserves, with significant upside in future developments. The Acquisition is expected to deliver an estimated 5% uplift to Free Cash Flow per share in 2024. Pro forma, Civitas expects to generate approximately $1.8B of Free Cash Flow in 2024 at $80/Bbl and $3.50/MMBtu. Increases Permian Basin scale, balancing Civitas' portfolio between premium Permian and DJ positions: The Acquisition will add approximately 44,000 net acres in the Midland Basin and current production of approximately 62 Mboe/d (approximately 50% oil). Pro forma for the Acquisition, Civitas' 2024 estimated Permian production is expected to be about 170 Mboe/d . Pro forma for the Acquisition, Civitas expects that its 2024 total company production will be 325 - 345 Mboe/d and total capital expenditures will be $1.95 - $2.25B. Adds premium, low breakeven oil inventory in the Midland Basin: The Acquisition will add an estimated 400 gross development locations located primarily in the Spraberry and Wolfcamp formations. Approximately 40% of the new locations have an estimated IRR of more than 40% at $70/Bbl WTI. Pro forma for the Acquisition, Civitas will have more than 1,200 high-quality oil development locations in the Permian Basin. Total consideration for the Acquisition is approximately $2.1B consisting of approximately 7.3M shares of common stock to be issued to Vencer and $1.55BN of cash, of which $1Bn will be due at closing. The remaining $550 million will be payable on January 3, 2025. Civitas has the option to accelerate the deferred cash payment to the closing of the Acquisition, which would lower the total purchase price by $50M to $2.05B. Civitas plans to fund the cash portion of the purchase price with a combination of debt and equity financings. Outlook

07:08 EDT PolyPid announces publication of preclinical data on D-PLEX100 - PolyPid announced the publication of positive preclinical results demonstrating, for the first time, the safety profile of D-PLEX100 and the PLEX technology platform in juvenile animals. These preclinical data were published in the peer-reviewed journal, International Journal of Toxicology, in a paper titled, "Preclinical In-Vivo Safety and Toxicokinetics of D-PLEX100 in an Abdominal Surgery Incision Model in Juvenile Miniature Swine." The safety and toxicokinetics of D-PLEX100 were tested following its administration via an abdominal incision to juvenile swine. The animals were evaluated for a period of nine months and no treatment-related adverse events were observed during this period. PolyPid's ongoing Phase 3 SHIELD II trial of D-PLEX100 for the prevention of surgical site infections is currently recruiting patients undergoing open abdominal colorectal surgery with large incisions. Top-line results are expected in mid-2024.

07:07 EDT PCS Edventures!.COM provides operational update - PCS Edventures!, announced the following updates on its operations. On September 28, 2023, the Company invoiced the Air Force Junior Reserve Officer Training Corps for their third order in the amount of $339,636. The Company has received payment on the JROTC's first two orders, in the amounts of $2,655,336 and $926,280, respectively. On September 28, 2023, the Company was notified by the JROTC that they had exercised the Year 1 option of the contract. The first year of the contract was completed on September 30, 2023. The Company believes that this option exercise is an indication of intention by the JROTC to place future orders with the Company, but such future orders cannot be guaranteed at this time. On October 3, 2023, the Company filed a Form 10-12g Registration Statement to register its securities with the SEC under the Securities Exchange Act of 1934, as amended. This type of registration statement typically becomes effective sixty days after the filing date and will require the Company to periodically file Forms 10-K, 10-Q, and 8-K among other filing requirements, including certain beneficial ownership filings of "affiliates" and 5% or more holders of the Company's common stock. On a preliminary basis, the Company generated slightly more than $3.77 million in revenue for the quarter ending September 30, 2023, a quarterly revenue record for the Company. While the Company is excited about its future business prospects, Management feels compelled to remind investors that the Company's business has strong seasonality during the year, with the quarter ending December 31st corresponding to the slowest revenue quarter. Last year, the Company reported revenue of $1.85 million for the quarter ending December 31st, of which $1.38 million was attributed to fulfilling a JROTC order. The Company has no order from the JRTOC to fulfill this year in the December 31st ending quarter and, thus, Management expects revenue in this quarter to be substantially less than last year's comparable quarter revenue. On August 2, 2023, the Company completed a transaction with a shareholder, purchasing 998,985 shares of the Company's common stock at 6.5 cents per share. This transaction was negotiated on June 14, 2023, after the shareholder approached the Company with an invitation to make an offer. This stock was subsequently retired, reducing the Company's shares of common stock outstanding to 124,733,494 as of September 30, 2023.

07:05 EDT OTC Markets Group welcomes Sandoz to OTCQX - OTC Markets Group announced Sandoz Group has qualified to trade on the OTCQX(R) Best Market.

07:04 EDT Freeline reports initial data from first cohort of Phase 1/2 GALILEO-1 trial - Freeline Therapeutics reported positive initial safety, tolerability and enzyme activity data from the ongoing Phase 1/2 GALILEO-1 trial evaluating FLT201, its adeno-associated virus gene therapy candidate, in Gaucher disease. In addition to demonstrating a favorable safety and tolerability profile, data from the first two patients in GALILEO-1 show that a single infusion of FLT201 led to several hundred-fold increases in GCase activity in plasma and normalization of GCase activity in leukocytes. Positive Initial Clinical Data for FLT201: The data reported today include assessments of safety, tolerability and GCase activity from the first two patients in GALILEO-1, which is a first-in-human, international, multicenter Phase 1/2 dose-finding study in people with Gaucher disease Type 1. Both patients were treated with a dose of 4.5x1011 vg/kg and have successfully come off their prior therapies. As of the September 27 data cutoff, the data demonstrated: Favorable safety and tolerability, with no infusion reactions and no serious adverse events as of 13 weeks post-dosing for patient 1 and six weeks post-dosing for patient 2. All treatment-related adverse events were Grade 1 and resolved without intervention. No elevations in liver transaminase levels during the same time periods. Alanine-transaminase and aspartate-transaminase levels remained in the normal range in both patients. Robust increases in plasma GCase levels. Patient 1 showed a nearly 700-fold increase over baseline to more than 70 mumol/L/h as of 12 weeks post-dosing. Patient 2 showed a similarly robust response, with a greater than 300-fold increase over baseline to approximately 30 mumol/L/h as of four weeks post-dosing. Normalization of leukocyte GCase activity, demonstrating cellular uptake of GCase from the plasma. Leukocyte GCase activity reached normal levels in patient 1 within four weeks of dosing and remained normal as of the last measurement. Similarly, leukocyte GCase activity in patient 2 reached normal levels within four weeks of dosing. Both patients had normal hemoglobin levels at baseline and have remained in the normal range at each weekly assessment, including those taken after coming off enzyme replacement therapy or substrate replacement therapy.

07:02 EDT GreenPower Motor delivers first EV Star to Forth - GreenPower Motor Company announced the delivery of the first all-electric, purpose-built EV Star to Forth, a nonprofit organization dedicated to the equitable advancement of clean transportation, for use at Hacienda CDC's Las Adelitas, a four-story, multifamily affordable housing development in Portland, Oregon. Once deployed, the EV Star will become part of Forth's Green Energy & Mobility Project that provides clean transportation opportunities and renewable energy solutions to two locations that offer shelter services and housing for historically underserved communities in Portland. The GEM project has been made possible through funding entirely by the Portland Clean Energy Community Benefits Fund. Approved by voters in 2018, the PCEF invests in community-led projects that reduce carbon emissions, create economic opportunity and helps make Portland more resilient as the city and residents face a changing climate.

06:51 EDT Eton Pharmaceuticals to acquire abbreviated NDA for Nitisinone Capsules - Eton Pharmaceuticals announced it has entered into an agreement to acquire an abbreviated new drug application for Nitisinone Capsules via Oakrum Pharma, LLC's Chapter 11 bankruptcy proceeding. The transaction has been approved by the bankruptcy court and is expected to be effective on October 12, 2023. The acquired product was approved by the U.S. FDA in May of 2023 for the treatment of hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine. It is estimated that less than 500 patients in the United States suffer from this ultra-rare condition. Eton expects to launch the product in the first quarter of 2024 and plans to offer its Eton Cares support program to all patients. The program is designed to help patients access treatment, providing prescription fulfillment services, insurance benefits investigation, educational support, and help in obtaining financial assistance for qualified patients, among other services. The current Nitisinone market is estimated to be over $50M annually, and Eton believes the company's commercial advantages, including its Eton Cares program, existing relationships with prescribers, and experienced sales force should allow it to capture a meaningful percentage of the market.

06:42 EDT MarketAxess reports Q3 total credit ADV of $11.2B, up 1.7% - Chris Concannon, CEO of MarketAxess, commented: "Our international businesses and our municipal bond offering registered solid ADV growth in the quarter, reflecting the benefits of our geographic and product diversification. Continued low levels of volatility dampened ETF market maker activity and favored select trading protocols, including portfolio trading. Adoption of our new trading platform, MarketAxess X-Pro, continues to expand. We are seeing early signs that our unique proprietary data is enhancing the client experience, including the execution of portfolio trades, and the final week of September was our second strongest week of credit trading volume ever. Additionally, we just completed the acquisition of Pragma, which we expect to accelerate our automation and client algo strategies. We believe that the rapid increase in interest rates since 2022 and the growing risks in financial markets will drive increased credit market volatility in the coming quarters." Reference Link

06:37 EDT BiomX completes patient dosing in Part 2 of Phase 1b/2a trial evaluating BX004 - BiomX announced the completion of patient dosing in Part 2 of the Phase 1b/2a trial evaluating the Company's novel phage cocktail, BX004, for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, in patients with cystic fibrosis, or CF. The Company remains on track to report results from Part 2 of the study in November 2023 at the IDWeek 2023 conference. The presentation title is Nebulized Phage Therapy for Patients with Cystic Fibrosis with Chronic Pseudomonas aeruginosa Pulmonary Infection: A Phase 1b/2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.

06:34 EDT Elanco announces process to amend corporate governing documents - Elanco Animal Health Incorporated announced that the Board of Directors has commenced a process to amend the Company's corporate governing documents as part of a comprehensive governance review following the Company's 2023 Annual Meeting of Shareholders. The Board expects to seek shareholder approval at the 2024 Annual Meeting of Shareholders for amendments to the Company's Articles of Incorporation that will: Commence a process to declassify the Board of Directors; Allow shareholders to amend the Company's Bylaws; and allow shareholders under certain circumstances to call special meetings of shareholders. More information regarding the proposals requiring shareholder approval will be included in the Company's proxy statement to be filed with the SEC prior to the 2024 Annual Meeting of Shareholders.

06:31 EDT Babcock & Wilcox subsidiary awarded $11M utility plant maintenance contract - Babcock & Wilcox Enterprises announced that its Canadian subsidiary, Babcock & Wilcox Canada, has been awarded a multi-year utility plant maintenance contract from Newfoundland and Labrador Hydro for its Holyrood Thermal Generating Station in Newfoundland, Canada, valued at nearly $11M with customer options for additional work. The company will manage and execute maintenance services for the 500-megawatt oil-fired power plant's boilers and boiler auxiliary equipment, including annual standard maintenance as well as capital projects for the plant's units over the next three years. B&W has extensive experience with all aspects of plant construction and maintenance - from large, complex projects, to small, quick-turnaround repairs and long-term plant maintenance services - and can provide solutions for any size facility anywhere in North America.

06:08 EDT Hercules Capital receives Baa3 investment grade credit rating from Moody's - Hercules Capital announced that Moody's Investors Service has reaffirmed Hercules an investment grade credit and corporate rating of Baa3 with a stable outlook, as well as its underlying analysis. The affirmed Baa3 rating reflects the company's strong earnings profile with a longer operating history than most rated business development company peers, solid underwriting and risk management as evidenced by low loan loss history, ample liquidity profile, and low leverage with stronger-than-peer median cushion against the minimum regulatory 150% asset coverage ratio. The rating also reflects Hercules' high proportion of first lien senior secured debt investments.

06:03 EDT Joby Aviation expands flight test program to include pilot on board - Joby Aviation announced it has expanded its flight test program to include flying with a pilot on board the aircraft, a critical step on the company's journey towards commercial operations. Four members of Joby's flight test team have now piloted flights on board Joby's pre-production prototype aircraft, completing a series of initial tests that included free thrustborne hovers and forward transitions to semi-thrustborne flight. The testing took place at the company's Pilot Production Facility in Marina, CA and complements ongoing flight testing at Edwards Air Force Base announced in September, where both Joby and U.S. Air Force pilots will demonstrate the aircraft's capabilities in realistic operating scenarios. To date, the majority of Joby's flight testing has been piloted remotely from a ground control station, using state-of-the-art communications technology and software. This has allowed the company to generate a vast amount of data on the performance of the aircraft across a broad range of flight conditions.

06:01 EDT Palantir, PwC collaborate on AI capabilities - Palantir announced the next milestone in its strategic Alliance with PwC, a global professional services firm. The collaboration will combine Palantir's latest AI capabilities with PwC's industry experience to help clients realize value with data and AI-enabled operations. The Alliance will see PwC leverage Palantir Foundry, the platform for integrating data, analytics, and operations, and Palantir's Artificial Intelligence Platform, or AIP, to help clients identify and action strategies for value creation and operational transformation.

05:31 EDT On Holding announces 2026 financial targets at investor day - On will host an investor day at On Labs in Zurich, Switzerland. By 2026, On intends to deliver on the following financial ambitions: Doubling net sales between 2023 and 2026 to at least CHF 3.55B, reflecting a CAGR of over 26% based on the outlook for the full fiscal year ending December 31, 2023; exceeding 60% gross profit margin by 2026; deliver economies of scale, with the ambition to reach 18%+ adjusted EBITDA margin by 2026. "We have an exciting product pipeline that includes running, training, and tennis footwear and apparel. Additionally, we believe there are huge opportunities to increase brand awareness and to expand through our multi-channel approach. We are enthusiastic about our continued growth." said Martin Hoffmann, Co-CEO and CFO. "The 2026 targets announced today continue to be above the long-term ambitions shared at the time of the IPO, and we view them as an intermediate step in our ambition to build a much bigger company in the future".

05:19 EDT Sanofi, Teva announce collaboration to co-develop TEV '574 - Sanofi (SNY) and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries (TEVA) announce a collaboration to co-develop and co-commercialize asset TEV '574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, two types of inflammatory bowel disease. Under the terms of the new collaboration agreement, Teva will receive an upfront payment of $500M and up to $1B in development and launch milestones. Each company will equally share the development costs globally and net profits and losses in major markets, with other markets subject to a royalty arrangement and Sanofi will lead the development of the Phase 3 program. Teva will lead commercialization of the product in Europe, Israel and specified other countries, and Sanofi will lead commercialization in North America, Japan, other parts of Asia and the rest of the world. The transaction will become effective after customary closing conditions are met. Initial program results are expected to be available in 2024.